8-K: ALX Oncology Appoints Alan Sandler as Chief Medical Officer, Announces CFO Departure

ALX Oncology appoints Alan Sandler as Chief Medical Officer, effective November 10, 2024, while also announcing the departure of Chief Financial Officer Peter Garcia.

Summary

• ALX Oncology has appointed Alan Sandler, M.D., as its new Chief Medical Officer, effective November 10, 2024.
• Dr. Sandler, previously a member of the Board, resigned from his board position to take on the role of Chief Medical Officer.
• His annual base salary will be $575,000, with a $50,000 signing bonus and eligibility for a 45% target cash bonus based on performance.
• He will also receive stock options for 700,000 shares, with 100,000 of those shares vesting in 2025.
• Peter Garcia, the former Chief Financial Officer, resigned effective November 8, 2024, due to personal reasons.
• Mr. Garcia will receive a lump sum payment of $479,646, COBRA coverage for up to 12 months, and accelerated vesting of stock options and restricted stock units.
• Mr. Garcia will also provide consulting services on an hourly basis for up to 12 months to ensure a smooth transition.
• The Board of Directors has been reduced to four members, with three being independent directors.
• The company has also announced the composition of its Audit, Compensation, and Corporate Governance and Nominating Committees.

Sentiment

Score: 7

Explanation: The appointment of a highly experienced Chief Medical Officer is a positive development, while the departure of the CFO is a neutral event with a plan for a smooth transition. The overall sentiment is positive but tempered by the potential challenges of executive transitions.

Positives

• The appointment of Alan Sandler as Chief Medical Officer brings significant experience in oncology and drug development to the company.
• Dr. Sandler's prior experience at Mirati Therapeutics, Zai Lab, and Genentech is expected to be valuable.
• The company has secured a consulting agreement with the departing CFO to ensure a smooth transition.
• The board has been restructured with a majority of independent directors.

Negatives

• The departure of the Chief Financial Officer, Peter Garcia, may create some uncertainty.
• The company will incur a one-time expense of $479,646 for the CFO's separation payment.
• The company will also incur costs for COBRA coverage for the departing CFO.

Risks

• The transition of key personnel, such as the CFO, could pose operational challenges.
• The company's future performance is dependent on the success of its clinical trials and the development of evorpacept.
• The company is subject to risks associated with clinical trials, regulatory approvals, and market competition.

Future Outlook

The company anticipates 2025 to be a transformational year and is focused on advancing the clinical development of evorpacept into late-stage clinical trials.

Management Comments

• Jason Lettmann, Chief Executive Officer, stated that Dr. Sandler's experience and leadership will be instrumental in achieving nearand longer-term objectives.
• Dr. Sandler expressed his excitement to continue the development of evorpacept with the vision to improve patient outcomes.

Industry Context

The appointment of a seasoned executive like Dr. Sandler reflects the ongoing trend of biotech companies strengthening their leadership teams to advance clinical programs. The departure of a CFO is not uncommon in the industry, and the company has taken steps to ensure a smooth transition.

Comparison to Industry Standards

• The compensation package for the new Chief Medical Officer, including a base salary of $575,000, a signing bonus of $50,000, and a 45% target bonus, is within the typical range for executive roles in the biotechnology industry.
• The severance package for the departing CFO, including a lump sum payment of $479,646 and extended benefits, is also consistent with industry standards for executive departures.
• The vesting of stock options and restricted stock units for the departing CFO is a common practice to ensure a smooth transition and to recognize past contributions.
• The restructuring of the board to include a majority of independent directors aligns with best practices in corporate governance.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may view the appointment of a new Chief Medical Officer positively, as it signals a commitment to advancing clinical programs.
• Employees may experience some uncertainty due to the departure of the CFO, but the consulting agreement should help ensure a smooth transition.
• Customers and suppliers are unlikely to be directly impacted by these changes.

Next Steps

• The company intends to file the employment offer letter and separation agreement with the SEC as exhibits to subsequent periodic reports.
• The company will continue to advance the clinical development of evorpacept.
• The company will continue to operate with the newly formed board committees.

Key Dates

Keywords

Chief Medical Officer, Chief Financial Officer, Alan Sandler, Peter Garcia, executive appointment, executive departure, oncology, biotechnology, evorpacept, clinical trials, board of directors, stock options, severance, compensation